Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia.
Gary J. Schiller
Research Funding - Ambit BioSciences
Martin S. Tallman
No relevant relationships to disclose
Stuart L. Goldberg
Research Funding - Ambit BioSciences
Alexander E. Perl
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Jean-Pierre Marie
No relevant relationships to disclose
Giovanni Martinelli
No relevant relationships to disclose
Richard A. Larson
Research Funding - Ambit BioSciences
Nigel Russell
No relevant relationships to disclose
Denise Trone
Employment or Leadership Position - Ambit BioSciences
Guy Gammon
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
Mark J. Levis
Consultant or Advisory Role - Ambit BioSciences (U)
Jorge E. Cortes
Consultant or Advisory Role - Ambit BioSciences (U); Astellas Pharma (U)
Research Funding - Ambit BioSciences; Astellas Pharma